

Sara M Tolaney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5239170/publications.pdf>

Version: 2024-02-01

147
papers

13,532
citations

39113

52
h-index

28425

109
g-index

149
all docs

149
docs citations

149
times ranked

15465
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	157.7	132
2	Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 117-124.	0.4	11
3	Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 303-311.	1.1	6
4	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1323-1334.	0.8	62
5	Clinical Significance of <i>PIK3CA</i> and <i>ESR1</i> Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant. <i>Clinical Cancer Research</i> , 2022, 28, 1500-1506.	3.2	35
6	Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. <i>Annals of Oncology</i> , 2022, 33, 234-238.	0.6	11
7	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. <i>Npj Breast Cancer</i> , 2022, 8, 23.	2.3	67
8	Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab. <i>Cancer Research</i> , 2022, 82, OT1-12-02-OT1-12-02.	0.4	0
9	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	2.3	8
10	Abstract P2-07-13: High-dimensional, single-cell analysis and transcriptional profiling reveal novel correlates of response to PARP inhibition plus PD-1 blockade in triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P2-07-13-P2-07-13.	0.4	0
11	Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. <i>Nature Biomedical Engineering</i> , 2022, 6, 257-266.	11.6	32
12	Auricular Acupuncture During Chemotherapy Infusion in Breast Cancer Patients: A Feasibility Study. , 2022, , .		0
13	Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives. <i>Future Oncology</i> , 2022, 18, 1927-1941.	1.1	3
14	Clinical trial data and emerging strategies: HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 281-291.	1.1	12
15	Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 45.	2.3	16
16	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 141-153.	1.1	5
17	Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. <i>Cell</i> , 2022, 185, 1694-1708.e19.	13.5	100
18	Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 106, 102395.	3.4	60

#	ARTICLE	IF	CITATIONS
19	Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 680-697.	1.6	12
20	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 195, 127-139.	1.1	15
21	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 63.	2.3	18
22	In Reply to Yilmaz et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 472.	0.4	0
23	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2408-2419.	0.8	42
24	Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go All In? Reply. <i>JAMA Oncology</i> , 2022, 8, 1221.	3.4	8
25	Impact of RxPONDER and monarchE on the Surgical Management of the Axilla in Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3361-3364.	0.8	14
26	The Effects of Diabetes and Glycemic Control on Cancer Outcomes in Individuals With Metastatic Breast Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2511-2521.	1.8	7
27	Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11
28	The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1453-1459.	3.0	39
29	DeepNeuro: an open-source deep learning toolbox for neuroimaging. <i>Neuroinformatics</i> , 2021, 19, 127-140.	1.5	26
30	Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 983-991.	3.2	29
31	Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 418-428.	3.2	16
32	Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. <i>Cancer Research</i> , 2021, 81, PD13-07-PD13-07.	0.4	33
33	The effects of releasing early results from ongoing clinical trials. <i>Nature Communications</i> , 2021, 12, 801.	5.8	4
34	Abstract PS7-01: Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study. , 2021, , .		2
35	Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond. <i>BioDrugs</i> , 2021, 35, 159-174.	2.2	30
36	Tumor mutational burden as a predictor of immunotherapy response in breast cancer. <i>Oncotarget</i> , 2021, 12, 394-400.	0.8	56

#	ARTICLE	IF	CITATIONS
37	Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. <i>Clinical Cancer Research</i> , 2021, 27, 3061-3068.	3.2	66
38	Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?. <i>Oncotarget</i> , 2021, 12, 873-875.	0.8	5
39	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	13.9	601
40	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. <i>Cancer Discovery</i> , 2021, 11, 2564-2581.	7.7	58
41	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 89.	3.6	10
42	The Immunology of Hormone Receptor Positive Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 674192.	2.2	68
43	Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 320-330.	1.4	14
44	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	0.8	76
45	Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial. <i>Breast Cancer Research</i> , 2021, 23, 87.	2.2	21
46	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021, 39, 2720-2731.	0.8	52
47	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
48	Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. <i>Npj Breast Cancer</i> , 2021, 7, 110.	2.3	20
49	Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?. <i>Journal of Clinical Oncology</i> , 2021, 39, 3541-3545.	0.8	6
50	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 103.	2.3	17
51	A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 45-52.	0.4	5
52	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	5.8	19
53	Reply to M. Tanaka et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01967.	0.8	0
54	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , 2021, 99, 102229.	3.4	15

#	ARTICLE	IF	CITATIONS
55	Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?. <i>Npj Breast Cancer</i> , 2021, 7, 120.	2.3	9
56	Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 752689.	1.3	2
57	59â€¦Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial. , 2021, 9, A67-A67.		0
58	Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1777-1787.	1.5	5
59	Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. <i>Frontiers in Oncology</i> , 2021, 11, 810023.	1.3	6
60	HER2-positive metastatic breast cancer: a comprehensive review. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 40-50.	0.3	20
61	A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 113-123.	1.1	26
62	Targeting HER2 heterogeneity in early-stage breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 545-554.	1.1	21
63	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4184-4193.	0.8	74
64	A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 238-245.	1.1	44
65	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptorâ€“Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5310-5319.	3.2	102
66	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptorâ€“Positive, <i>ERBB2</i>-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1598.	3.4	84
67	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2âˆ², Node-Positive, High-Risk, Early Breast Cancer (monarchE). <i>Journal of Clinical Oncology</i> , 2020, 38, 3987-3998.	0.8	478
68	Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 923-930.	1.1	5
69	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1174-1193.	7.7	176
70	A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. <i>Oncologist</i> , 2020, 25, 652-660.	1.9	11
71	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	15.2	83
72	Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. <i>Clinical Breast Cancer</i> , 2020, 20, 395-401.e3.	1.1	7

#	ARTICLE	IF	CITATIONS
73	Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go. <i>Current Treatment Options in Oncology</i> , 2020, 21, 59.	1.3	12
74	Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2565-2572.	3.2	138
75	HER2-Low Breast Cancer: Pathological and Clinical Landscape. <i>Journal of Clinical Oncology</i> , 2020, 38, 1951-1962.	0.8	353
76	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchHER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 763-775.	5.1	144
77	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 705-715.	1.1	62
78	A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS1105-TPS1105.	0.8	4
79	Role of Immunotherapy in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 479-489.	2.3	295
80	Utilization of tumor genomics in clinical practice: an international survey among ASCO members. <i>Future Oncology</i> , 2019, 15, 2463-2470.	1.1	12
81	<p>Evidence to date: talazoparib in the treatment of breast cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5177-5187.	1.0	30
82	CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?. <i>Lancet Oncology</i> , The, 2019, 20, 1479-1481.	5.1	7
83	Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. <i>Clinical Breast Cancer</i> , 2019, 19, 399-404.	1.1	27
84	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1132.	3.4	285
85	The Immune Microenvironment in Hormone Receptorâ€“Positive Breast Cancer Before and After Preoperative Chemotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4644-4655.	3.2	76
86	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitorâ€“Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019, 7, 1214-1220.	1.6	44
87	Localâ€“regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	1.1	30
88	Personalized chemotherapy in triple-negative breast cancer: are we ready for prime time?. <i>Stem Cell Investigation</i> , 2019, 6, 4-4.	1.3	1
89	HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983351.	1.4	240
90	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. <i>Clinical Breast Cancer</i> , 2019, 19, 268-277.e1.	1.1	13

#	ARTICLE	IF	CITATIONS
91	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	0.8	229
92	Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 741-751.	13.9	542
93	PD-L1 Testing in Patients with Breast Cancer: Controversies and Current Practice. <i>Current Breast Cancer Reports</i> , 2019, 11, 353-357.	0.5	2
94	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 74.	3.4	557
95	Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up. <i>JAMA Oncology</i> , 2019, 5, 334.	3.4	206
96	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019, 40, 17-65.	8.9	349
97	Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the <i>PRF1A91V</i> gene polymorphism. <i>Journal of Medical Genetics</i> , 2019, 56, 39-42.	1.5	25
98	Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1004-1004.	0.8	19
99	Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1115-TPS1115.	0.8	12
100	OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
101	De-escalating treatment in the adjuvant setting in HER2-positive breast cancer. <i>Future Oncology</i> , 2018, 14, 937-945.	1.1	5
102	Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. <i>Cancer</i> , 2018, 124, 1111-1121.	2.0	72
103	Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	153
104	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. <i>JAMA Oncology</i> , 2018, 4, 173.	3.4	753
105	Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib. <i>Clinical Imaging</i> , 2018, 48, 44-47.	0.8	2
106	Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2-Advanced breast cancer: a review. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 607-614.	1.1	18
107	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	0.8	162
108	Optimal treatment of early stage HER2-positive breast cancer. <i>Cancer</i> , 2018, 124, 4455-4466.	2.0	52

#	ARTICLE	IF	CITATIONS
109	Database Selection and Heterogeneityâ€”More Details, More Credibilityâ€”Reply. <i>JAMA Oncology</i> , 2018, 4, 1295.	3.4	2
110	Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5292-5304.	3.2	73
111	CDK4/6 inhibition in breast cancer: current practice and future directions. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878645.	1.4	218
112	Abemaciclib for the treatment of HR+/HER2- breast cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 151-161.	0.4	2
113	Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 10.	2.3	95
114	TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1011-1011.	0.8	63
115	Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1059-1059.	0.8	38
116	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2â” Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5218-5224.	3.2	492
117	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 3520-3528.	3.2	19
118	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140.	1.6	114
119	Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. <i>Nature Communications</i> , 2017, 8, 1324.	5.8	584
120	Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. <i>Oncologist</i> , 2017, 22, 25-32.	1.9	79
121	Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors. <i>Cancer</i> , 2017, 123, 1249-1258.	2.0	87
122	Optimal Management of Early and Advanced HER2 Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 76-92.	1.8	17
123	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2141-2148.	0.8	283
124	Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. <i>Cancer Research</i> , 2017, 77, 2986-2986.	0.4	89
125	Randomized trial of a physical activity intervention in women with metastatic breast cancer. <i>Cancer</i> , 2016, 122, 1169-1177.	2.0	87
126	Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Nonâ€”Small Cell Lung Cancer, and Other Solid Tumors. <i>Cancer Discovery</i> , 2016, 6, 740-753.	7.7	565

#	ARTICLE	IF	CITATIONS
127	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 305-312.	1.1	37
128	Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. <i>Cancer Cell</i> , 2016, 29, 255-269.	7.7	356
129	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3227-3237.	3.2	85
130	Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 29.	3.4	68
131	Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1009-1009.	0.8	87
132	Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14325-14330.	3.3	206
133	The evolving understanding of small HER2-positive breast cancers: matching management to outcomes. <i>Future Oncology</i> , 2015, 11, 3261-3271.	1.1	2
134	Optimizing the Management of Metastatic HER2-Positive Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 190-202.	0.5	0
135	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 134-141.	13.9	598
136	Acute appendicitis secondary to metastatic carcinoma of the breast: Case report and review of the literature. <i>Cancer Treatment Communications</i> , 2015, 4, 41-45.	0.4	2
137	Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. <i>Investigational New Drugs</i> , 2015, 33, 1108-1114.	1.2	44
138	Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 13-21.	0.8	782
139	A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer. <i>Cancer Medicine</i> , 2014, 3, 293-299.	1.3	6
140	Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer- CALGB 40302 (Alliance). <i>Journal of Clinical Oncology</i> , 2014, 32, 3959-3966.	0.8	77
141	Breast Cancer Chemotherapy and Your Heart. <i>Circulation</i> , 2014, 129, e680-2.	1.6	6
142	New HER2-Positive Targeting Agents in Clinical Practice. <i>Current Oncology Reports</i> , 2014, 16, 359.	1.8	16
143	Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).. <i>Journal of Clinical Oncology</i> , 2014, 32, 506-506.	0.8	13
144	Lymphopenia Associated with Adjuvant Anthracycline/Taxane Regimens. <i>Clinical Breast Cancer</i> , 2008, 8, 352-356.	1.1	25

#	ARTICLE	IF	CITATIONS
145	Sarcoidosis Mimicking Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2007, 7, 804-810.	1.1	34
146	Pneumocystis Carinii Pneumonia During Dose-Dense Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5330-5331.	0.8	20
147	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 0, , .	3.4	51